Check Point Care at MEDICA 2025: how EIC support helped open pilot talks and commercial leads, and what still needs proving
- ›Check Point Care, an EIC Accelerator awardee from Bulgaria, used the EIC International Trade Fairs Programme at MEDICA 2025 to accelerate market outreach.
- ›Through EIC matchmaking and pavilion visibility the company opened pilot discussions with major European hospitals and obtained interest from global device manufacturers and distributors.
- ›Check Point Care reports more than 10,000 pending orders for its next generation wearable monitoring devices and planned pilots starting at about 1,000 patients.
- ›The company expects MDR certification in September and is working to close an EUR 8.5 million Series A round to finance commercial scale-up.
- ›The EIC facilitated introductions and provided business acceleration services, but clinical validation, regulatory approval, reimbursement and supply chain scale remain the main risks to commercialisation.
Check Point Care at MEDICA 2025: from showcase to market conversations
Check Point Care is a Bulgarian healthtech company backed by the EIC Accelerator that develops AI‑powered remote patient monitoring hardware and software. At MEDICA 2025 the company exhibited through the EIC Pavilion and used EIC matchmaking services to secure meetings with hospital groups, major device manufacturers, distributors and potential investors. The company reports a sharp increase in commercial interest following the event and says it has initiated pilot discussions with prominent European hospitals and received over 10,000 pending orders for its next generation wearable monitoring devices.
What the company showcased and why it matters
Check Point Care’s platform is presented as a hospital-at-home enabler. It combines a medical-grade wearable system that streams more than 19 physiological parameters, an AI analytics engine producing thousands of digital biomarkers and a virtual ward interface for clinicians. The next generation product under MDR certification is a lightweight bracelet paired with a chest device. The company emphasises applications in cardiology, oncology, transplant monitoring and chronic disease management where continuous physiological surveillance can change discharge and follow-up pathways.
Outcomes reported after MEDICA 2025
According to the company and EIC communications, MEDICA produced several concrete leads. Check Point Care says it: secured meetings with major medical device companies to explore integrations; engaged with university hospitals in Germany, Sweden and the United Kingdom to discuss pilot deployments starting at roughly 1,000 patients; advanced talks in Italy with a private hospital chain and a regional public hospital already running studies with the technology; and attracted interest from at least 10 qualified distributors across multiple markets. The firm also reports more than 10,000 pending orders for its next generation wearable devices.
| Metric | Figure reported | Note |
| Pending orders | More than 10,000 | Company statement. Pending orders are not the same as firm contracts with payment and delivery commitments |
| Initial pilot scale | About 1,000 patients | Planned pilots with leading university hospitals; pilots are the validation step rather than mass roll-out |
| MDR certification | Expected in September 2026 | Essential for market access in the EU for medical devices. Timing and scope matter |
| Series A target | EUR 8.5 million | Planned round to finance business development and scaling |
| Priority markets | UK, Germany, Scandinavia, Benelux | Typical early adoption markets for clinical digital health in Europe |
What the EIC provided and why that helps
Check Point Care participated in the EIC International Trade Fairs Programme and exhibited at the EIC Pavilion. The EIC programme bundles exhibition space, curated matchmaking, pitching opportunities and visibility. It also connects awardees to Business Acceleration Services, including coaching, investor outreach and ecosystem partnerships such as the EIC Scaling Club and ACCESS+ co‑funded services. For companies pushing from lab to hospital pilots, the practical value of introductions to procurement teams, distributors and corporate partners can be substantial.
Technical, regulatory and clinical hurdles to watch
Progress at a trade fair and early pilot interest are important but not decisive. For a digital health product that combines hardware, AI and clinically actionable outputs, several bottlenecks determine whether pilot interest converts to sustainable adoption and revenue. These include regulatory certification, clinical validation, reimbursement and procurement, data protection and integration with clinical systems, and manufacturing and distribution scale.
Other specific risks to monitor include the following. Pending orders can be conditional on regulatory clearance or procurement approvals. Clinical pilots must produce replicable outcomes and clear value propositions for hospitals, for example reductions in readmissions, length of stay or avoidable escalations, coupled with cost analyses. Reimbursement and procurement cycles in Europe are slow and heterogeneous. Integration with electronic health records and nurse workflows is often the practical barrier to clinical adoption. Data protection under GDPR and forthcoming AI rules will require contractual and technical attention. Finally, scaling requires manufacturing quality processes, supply chain resilience and logistics for timely device delivery and servicing.
Commercial strategy and financing
Check Point Care says it is prioritising the United Kingdom and Germany for initial commercialisation, followed by Scandinavia and the Benelux. The company plans a distribution plus direct hospital engagement strategy, using pilots as the evidence base for broader rollouts. To support that expansion it is working to close an €8.5 million Series A round. EIC Business Acceleration Services were cited as helping sharpen messaging, investor outreach and access to industrial partners.
Why this case matters for the EU innovation ecosystem
The Check Point Care story illustrates how EIC instruments try to move deep tech ventures from research funding to commercial validation. EIC trade fair support can open doors that are otherwise hard to reach for small companies. The EIC brand and curated pavilion introduce credibility in front of hospitals and corporates. Business acceleration services and investor matchmaking are intended to crowd in private capital and corporate partnerships. For the ecosystem, success stories that convert pilots into scaled deployments and exits would validate this blended public support model.
At the same time the case highlights persistent structural frictions for healthtech scale-up in Europe. Regulatory bottlenecks, clinical evidence requirements, heterogenous procurement rules and conservative buyer behaviour slow commercialisation. Public support can accelerate introductions and early pilots, but converting leads into repeatable contracts requires demonstrable clinical and economic value, predictable regulatory status, and operational scale.
Bottom line and what to watch next
Check Point Care’s MEDICA engagement is a useful example of how EIC trade fair and BAS interventions can amplify market visibility for promising healthtech firms. The company has tangible leads and a development roadmap that includes MDR certification and a Series A fundraise. Observers should treat the reported 10,000 pending orders and planned pilot numbers as early indicators rather than final outcomes. The next material milestones to validate the company’s commercial claims will be MDR certification details, signed pilot agreements with hospitals, concrete procurement or distributor contracts with delivery schedules, the closing of the Series A round, and published clinical results from initial pilots demonstrating patient benefit or health system savings.
| Key milestone | Company statement / timing | Why it matters |
| MDR certification | Expected September 2026 | Necessary for EU market entry and for many procurement processes |
| Initial hospital pilots | Planned from MEDICA leads, ~1,000 patients | Clinical validation and operational proof of concept |
| Distributor agreements | Interest from at least 10 distributors | Needed for market coverage and fulfilment |
| Series A | Target EUR 8.5 million | Funding to scale sales, regulatory work and manufacturing |
| Public evidence | Clinical study results pending | Essential to convince payers and large hospital buyers |
Practical tips for other deep tech founders using trade fairs
1) Use curated pavilions and official branding when possible. Public programmes lend credibility and can improve access to senior buyers. 2) Prepare clear, short clinical and economic value propositions for buyers, not technology features. 3) Treat expressions of interest as step one. Convert them by aligning regulatory milestones, pilot protocols, procurement timelines and financing. 4) Discuss data governance and interoperability early with hospital IT teams. 5) Plan manufacturing and logistics timelines in parallel with pilot agreements to avoid fulfilment gaps.
Check Point Care’s trajectory will be instructive for policy makers and investors tracking the effectiveness of the EIC model in converting deep tech research into scaleable medical products. The EIC role in matchmaking and visibility is clear. Whether these introductions translate into durable clinical deployments, sustainable revenues and broader health system impact will depend on the firm delivering on regulatory, clinical and operational milestones over the coming 12 to 24 months.